Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
So this drop, is it investors worried about the delay and managing risk, or traders exploiting the situation and trying to force the price down and precipitate a capitulation ?
Why are people stressing about hoping it may go lower before they buy some. This is just crazy cheap this close to a potential turning point, heralded for ages, but maybe now almost upon us. Many of us have been buying for several years, that a good proportion are somewhat underwater is cruel, but it is what it is. Getting this price now is a gift if you believe in the tech.
There is a real chance that this could be reported by phase 1b. If doxarubicin does continue to work beyond its currently known limits then maybe. There is a very good chance that if 3996 lives up to its promise results would strart to appear very early in target patients, as it is a known powerful class of drug that has simply never been able to be used against any solid tumors. AVA6000, wonderful though it promises to be, is but the taster on this menu.
Plus, they have Orphan designation for STS, and have good shot at rapid approval if the results warrant, so diluting your already small pool of patients with those with other cancers would be the dumbest of dumb moves imaginable. ie it is not happening.
Plus, they have Orphan designation for STS, and have good shot at rapid approval if the results warrant, so diluting your already small pool of patients with those with other cancers would be the dumbest of dumb moves imaginable. ie it is not happening.
Sure to be more milestones as the company add new targets. The Avacta percentage will depend on how much more cash funding is required, so how long is a piece of string. Anything around the 20% mark would be a major result. The potential here is huge, and Avacta get their share without draining any cash, save the labout and lab cost of working up the affimer characterisation. It is just amazing in my book that this is a background / footnote project for most people, other companies would be jumping and shouting.
Some years ago AS made the unfortunate comparison with Roche, saying that with scale up capital Avacta could be a competitor. The remark has been done to death by several posters, and I wince whenever it is repeated.